Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Advanced Gastrointestinal Tumors
Interventions: Minnelide™ 001; Drug
Lead sponsor: Minneamrita Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Scottsdale, Arizona • Minneapolis, Minnesota

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ibudilast; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Patchogue, New York

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 22 more

Conditions: Cerebral Palsy
Interventions: Dysport Injectable Product; Drug
Lead sponsor: Columbia University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Small Cell Lung Carcinoma
Interventions: Amuvatinib; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Louisville, Kentucky + 4 more

Conditions: HIV Infections
Interventions: Atazanavir+ritonavir, Lopinavir+ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Interventions: FCN-159; Drug
Lead sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • St. Petersburg, Florida + 2 more

Conditions: Age-Related Maculopathy
Interventions: Rheopheresis; Device
Lead sponsor: OccuLogix; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 18 more

Conditions: Femur Fracture
Interventions: Ultrasound-Guided Fascia Iliaca Compartment Nerve Block; Procedure
Lead sponsor: Zachary Binder; Other
Eligibility: 4 Years to 17 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 6 more

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears; Drug
Lead sponsor: Senju USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Respiratory Syncytial Virus Infections
Interventions: Placebo, Active; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day to 60 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Los Angeles, California • St Louis, Missouri

Conditions: COVID-19
Interventions: Brilacidin, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Winfield, Illinois • Toledo, Ohio

Conditions: Metastatic Melanoma, Advanced Melanoma
Interventions: Nivolumab, Relatlimab, Ipilimumab, Signatera genome MRD assay; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibromyalgia
Interventions: [S,S]-Reboxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 136
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 111 more

Conditions: Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 127
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more

Conditions: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Interventions: Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 0 Years to 17 Years
U.S. locations: 4
States / cities: Aurora, Colorado • Cincinnati, Ohio • Memphis, Tennessee + 1 more

Conditions: Alzheimer Disease
Interventions: 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos; Drug
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: End Stage Renal Disease
Interventions: AAT-023 solution (Zuragen), Heparin; Device · Drug
Lead sponsor: Ash Access Technology; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 22
States / cities: Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more

Conditions: Healthy
Interventions: Diclofenac Sodium Gel; Drug
Lead sponsor: Amzell; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Pain, Cancer
Interventions: PMI-150 (intranasal ketamine), placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more

Conditions: Endometrial Hyperplasia
Interventions: BAY865028, Medroxyprogesterone acetate; Combination Product · Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more

Conditions: End Stage Renal Disease
Interventions: Theranova 400 dialyzer, Elisio-17H dialyzer; Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Corona, California • Riverside, California • Bloomfield, Connecticut + 15 more

Search by objective public record fields.

Study of Minnelide™ in Patients With Advanced GI Tumors

A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy

A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis

Study Comparing Ultrasound-guided FICNB Block to Systemic Analgesia in Treatment of Pediatric Femur Fracture

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients